Valsartan: In Children and Adolescents with Hypertension
Pediatric Drugs, 04/25/2012
Clinical Article
Croxtall JD – Treatment with valsartan for up to 52 weeks was well tolerated in children and adolescents with hypertension.
Methods- In two, randomized, double-blind trials, a once-daily regimen of valsartan reduced the blood pressure (BP) of children and adolescents with hypertension.
- In one trial in hypertensive children and adolescents aged 6–16 years, significant dose-dependent reductions from baseline in mean sitting systolic BP (msSBP) were observed for recipients of valsartan following 2 weeks' treatment (primary endpoint).
- There were corresponding dose-dependent and significant reductions in mean sitting diastolic BP.
- In addition, the proportion of patients achieving an msSBP <95th percentile for age, sex, and height at week 12 was not significantly different between recipients of valsartan and enalapril (67% vs 70%).
